Irbesartan Hexal

Irbesartan, the active ingredient in Irbesartan Hexal, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It lowers blood pressure and provides renal protection, particularly in patients with hypertension and diabetic kidney disease. It is indicated for the management of high blood pressure and for slowing the progression of diabetic nephropathy, offering a well‑tolerated oral option for adult patients.

GNH USA supplies Irbesartan Hexal as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide with rigorous quality assurance and regulatory adherence.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and protect kidney function.

- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Diabetic nephropathy: slows decline of renal function and reduces proteinuria in type 2 diabetes. - Cardiovascular risk reduction in hypertensive patients: lowers incidence of stroke and myocardial infarction when combined with appropriate therapy.

Irbesartan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Hyperkalemia - Acute kidney injury - Angioedema

When prescribing Irbesartan, clinicians should consider several safety measures.

- Renal function monitoring: assess serum creatinine and eGFR before and during therapy. - Serum potassium monitoring: check potassium levels regularly, especially when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy: avoid use; drug is contraindicated in pregnancy due to fetal toxicity risk. - Elderly patients: start at lower dose and titrate cautiously. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors: combined use can increase risk of renal dysfunction and hyperkalemia. - Lithium: can raise lithium levels and precipitate toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations. - Thiazide diuretics: may enhance hypotensive effect and require dose adjustment.